An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the efficacy, safety and pharmacokinetics of BIBW
2992, a dual, irreversible EGFR- and HER2-inhibitor, in two cohorts of patients with
HER2-negative breast cancer after failure of no more than three regimen of prior
chemotherapy.